The American Society of Clinical Oncology, based in Alexandria, Virginia, has criticized insurers’ clinical pathways for cancer practitioners for emphasizing cost control over the best interests of the patient. These guidelines often delay care, serve as a barrier to better outcomes, and fail to account for individual patient differences. Additionally, the oncology group noted the lack of transparency in the guidelines’ development. You can read more here.
Last Updated on May 7, 2020 by Aimed Alliance
